The invention relates to substituted 6-(2-hydroxybenzylamino)purines of general formula I, to their activity as cyclin-dependent kinases 2, 5, 7 and 9 inhibitors and to their use as medicaments, particularly in the treatment of disorders involving cell proliferation or inflammation. The invention further includes pharmaceutical compositions containing the substituted 6-(2-hydroxybenzylamino)purines.
本发明涉及一般式I的取代6-(2-羟基
苯基
氨基)
嘌呤,其作为周期素依赖性激酶2、5、7和9的
抑制剂的活性以及它们在药物治疗中的使用,特别是在涉及细胞增殖或炎症的疾病治疗中。本发明还包括含有取代6-(2-羟基
苯基
氨基)
嘌呤的药物组合物。